8-K: Arvinas ARV-393 & Glofitamab Show Strong Preclinical Synergy

Arvinas, Inc. announced positive preclinical data for its PROTAC BCL6 degrader ARV-393 in combination with glofitamab, demonstrating enhanced tumor growth inhibition and regression in lymphoma models.

Summary

• Arvinas presented preclinical data for ARV-393, a PROTAC BCL6 degrader, combined with glofitamab, a CD20CD3 bispecific antibody, at the 67th American Society of Hematology (ASH) Annual Meeting.
• The combination showed significantly enhanced tumor growth inhibition (TGI) and increased rates of tumor regression in a humanized high-grade B-cell lymphoma (HGBCL) cell line-derived xenograft (CDX) model compared to either agent alone.
• At a 3 mg/kg dose of ARV-393 combined with 0.15 mg/kg glofitamab, TGI reached 81% with concomitant dosing and 91% with sequential dosing, significantly higher than 38% for single-agent ARV-393 and 36% for glofitamab alone.
• At a higher ARV-393 dose (6 mg/kg) combined with glofitamab (0.15 mg/kg), tumor regressions were observed in 10 of 10 mice with concomitant dosing and 7 of 8 mice with sequential dosing, compared to 5 of 11 mice for single-agent ARV-393 and 0 of 11 mice for glofitamab alone.
• RNA sequencing and biomarker analyses indicated that ARV-393 upregulated CD20 expression and genes promoting interferon signaling and antigen presentation, while downregulating proliferation-associated gene sets, contributing to synergistic antitumor activity.
• ARV-393 is currently in a Phase 1 clinical trial for relapsed/refractory non-Hodgkin lymphoma.
• Arvinas plans to share clinical data from the ongoing Phase 1 trial at a medical congress in 2026.
• A glofitamab combination cohort for patients with diffuse large B-cell lymphoma (DLBCL) will be added to the ongoing Phase 1 clinical trial of ARV-393 in 2026.

Sentiment

Score: 8

Explanation: The filing presents very strong positive preclinical data for a combination therapy, demonstrating significant efficacy improvements over single agents. The clear plans for advancing to a combination clinical cohort in 2026 further enhance the positive sentiment, indicating strong pipeline progression and potential for addressing an unmet medical need. The only mitigating factor is that these are preclinical results, which do not guarantee clinical success.

Positives

• The combination of ARV-393 and glofitamab achieved significantly enhanced tumor growth inhibition (TGI) of up to 91% in preclinical models, substantially outperforming single agents.
• Increased rates of tumor regression were observed with the combination, with 100% regression in one dosing regimen at a higher ARV-393 dose.
• Preclinical data suggest strong mechanistic synergies, with ARV-393 upregulating CD20 expression and genes promoting T-cell engagement and antigen presentation.
• The results provide a strong rationale for a chemotherapy-free combination approach for diffuse large B-cell lymphoma (DLBCL), addressing a significant unmet medical need.
• Plans to initiate a combination cohort in the ongoing Phase 1 clinical trial in 2026 demonstrate a clear path forward for clinical development.

Risks

• Actual results or events could differ materially from forward-looking statements due to various risks and uncertainties.
• There is no guarantee that Arvinas will successfully conduct and complete development for its product candidates, including ARV-393.
• Drug development involves inherent risks, including unexpected costs or delays in clinical trials.
• Positive data from preclinical or early clinical studies are not necessarily predictive of the results of later clinical studies or future clinical trials.
• The company's ability to protect its intellectual property portfolio is crucial for its success.
• Reliance on third parties for various aspects of drug development and manufacturing poses risks.
• There is a risk that Arvinas may not be able to raise capital when needed.
• The company's cash and cash equivalents may not be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements.

Future Outlook

Arvinas plans to advance ARV-393 by sharing clinical data from its ongoing Phase 1 trial in 2026 and initiating a new combination cohort with glofitamab for diffuse large B-cell lymphoma patients within the same trial in 2026, aiming for a chemotherapy-free treatment strategy.

Management Comments

• Noah Berkowitz, M.D., Ph.D., Chief Medical Officer: "By pursuing a chemotherapy-free combination approach, we aim to address this significant unmet need and potentially offer patients a more targeted, better-tolerated therapeutic alternative. The initiation of our Phase 1 combination clinical trial, planned for 2026, represents an important step toward defining the potential of ARV-393 in the treatment of this aggressive form of lymphoma."
• Angela Cacace, Ph.D., Chief Scientific Officer: "We believe these results underscore the potential for ARV-393 and provide a strong mechanistic rationale for exploring ARV-393 in combination with glofitamab as a chemotherapy-free treatment strategy for patients with diffuse large B-cell lymphoma. These preclinical results support our belief in the clinical potential and combinability of ARV-393 and the possibility to provide real benefit to patients in need."

Industry Context

The announcement highlights Arvinas's strategy to address the significant unmet need for patients with diffuse large B-cell lymphoma (DLBCL) who have limited options after standard therapies fail. The pursuit of a chemotherapy-free combination approach with a PROTAC degrader and a bispecific antibody positions Arvinas at the forefront of innovative targeted therapies, potentially offering a more targeted and better-tolerated alternative in the competitive oncology landscape.

Stakeholder Impact

• **Shareholders**: Positive impact due to strong preclinical data validating the PROTAC platform and ARV-393's potential, potentially increasing company valuation and investor confidence.
• **Patients**: Potential for a new, more effective, and chemotherapy-free treatment option for aggressive forms of lymphoma, particularly diffuse large B-cell lymphoma (DLBCL), addressing a significant unmet medical need.
• **Medical Community**: The data supports further investigation into PROTAC-mediated BCL6 degradation in combination with T-cell engaging therapies, potentially influencing future treatment paradigms for B-cell lymphomas.

Next Steps

• Share clinical data from the ongoing Phase 1 clinical trial of ARV-393 in patients with relapsed/refractory non-Hodgkin lymphoma at a medical congress in 2026.
• Add a glofitamab combination cohort for patients with diffuse large B-cell lymphoma (DLBCL) to the ongoing Phase 1 clinical trial of ARV-393 in 2026.

Key Dates

Recommendation

The preclinical data for ARV-393 in combination with glofitamab are exceptionally strong, showing significantly enhanced tumor growth inhibition and regression rates compared to monotherapy. This robust mechanistic synergy provides a compelling rationale for its advancement into a combination clinical cohort in 2026, targeting a high-unmet-need area like DLBCL with a chemotherapy-free approach. For a clinical-stage biotechnology company, such positive preclinical validation and a clear, accelerated path to clinical development for a promising asset are highly indicative of future value creation and warrant a 'strong buy' recommendation, despite the inherent risks of drug development.

Keywords

Arvinas, ARV-393, PROTAC, BCL6 degrader, glofitamab, lymphoma, HGBCL, DLBCL, preclinical data, ASH, oncology, biotechnology, targeted protein degradation